Celgene/Receptos Deal Seen as a Positive for Arena Pharma (ARNA), Piper Jaffray Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Celgene (CELG) PT Raised to $142 at UBS on Receptos (RCPT); Only Worry is Competing Bid
July 15, 2015 9:02 AM EDTUBS analyst Matthew Roden reiterated a Buy rating and boosted his price target on Celgene (NASDAQ: CELG) to $142.00 (from $130.00) following the acquisition of Receptos.
Roden commented, "In our view, Celgene's acquisition of Buy-rated Receptos for $7.2bn ($232/share) is a positive, as it... More
